Mortality in acute and chronic management of idiopathic pulmonary fibrosis
Respiratory Ventilatory Strategies in Acute and Chronic Respiratory Failure in Idiopathic Pulmonary Diseases: A Practical Approach, NOVA Publications , ss.343-347, 2020
- Yayın Türü: Kitapta Bölüm / Araştırma Kitabı
- Basım Tarihi: 2020
- Yayınevi: NOVA Publications
- Sayfa Sayıları: ss.343-347
- Anahtar Kelimeler: Interstitial lung diseases, Management of idiopathic pulmonary fibrosis, Mortality of idiopathic pulmonary fibrosis, Prognosis
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Idiopathic pulmonary fibrosis (IPF) is a well-known interstitial lung disease (ILD) and has the worst prognosis of all the ILDs. The median life expectancy is approximately 3-5 years after diagnosis. In the last decade new anti-fibrotic drugs have led to an improvement in the health-related quality of life (HRQoL) and a slowing of IPF disease progression. Despite advances in diagnostic technology and medical treatment there is still a high mortality rate, i.e., nearly 50%, in cases of acute exacerbation of IPF or infectious conditions due to immunosuppression therapy, which require intubation for mechanical ventilation in the intensive care unit. As IPF progresses, supplemental oxygen treatment is required (when pulse oxygen saturation is below 88% at rest and in room air) and these IPF patients' have a decreased life expectancy. IPF patients 60 years or older and with acute respiratory failure have a shorter survival and a higher mortality rate. IPF is a crucial health problem that requires further research and attention to prevent mortality.